Get all your news in one place.

100’s of premium titles.
One app.

Get all your news in one place.

100’s of premium titles. One news app.

The Latest Breaking News from Novo

Novo Nordisk Dives On Rare Miss As Pricing Pressure Weighs On Ozempic, Wegovy

Novo Nordisk stock tumbled Wednesday after the drugmaker reported a rare sales miss for its two biggest moneymakers, Ozempic and Wegovy.

Investors Business Daily

Novo Nordisk cuts profit outlook after weaker sales of weight-loss drug Wegovy

Danish company, which also makes Ozempic, faces increasing competition from US rival Eli Lilly

The Guardian - UK

Novo Nordisk hits out as Dutch agency advises against insurance cover for Wegovy

Novo had last year applied to Dutch authorities for a coverage of the drug under its insurance

The Independent UK

From analysis to the latest developments in health,
read the most diverse news in one place.

Novo Nordisk Stock Pops After Weight-Loss Drug Cuts Dementia Risk In Yearlong Study

Novo Nordisk stock popped Friday after a study showed its diabetes and weight-loss drug could lower the risk of developing dementia.

Investors Business Daily

Will Novo Nordisk's (NVO) Q2 Earnings Reflect Its Market Potential?

With strong first-quarter results and promising growth in its diabetes and obesity treatments, all eyes are on Novo Nordisk’s (NVO) to see if the pharmaceutical giant can maintain its momentum. Will the upcoming second-quarter earnings report reflect its market potential? Learn more to find out….

StockNews.com

Weight-loss war heats up as Wegovy rival found to lead to faster and greater results

Shares in Novo Nordisk were down 1.1% after the study

The Independent UK

Novo, Lilly Tumble After Study Ties Blindness Disorder To Weight-Loss Drugs

Novo Nordisk stock skidded Wednesday after a new study suggests its diabetes and weight-loss drug can lead to a blindness-causing disease.

Investors Business Daily

Read news from The Economist, FT, and more,
with one subscription

Novo, Lilly Fall After Biden Slams Duo For 'Unconscionably High' Drug Prices

Novo Nordisk stock fell Tuesday after Joe Biden and Bernie Sanders slammed the drugmaker and Eli Lilly for high prices of weight-loss drugs.

Investors Business Daily

The Future of Weight-Loss Drugs for Investors

Weight-loss drugs’ impact could reach far beyond their target user, potentially creating headwinds for shares of snack makers and packaged-food firms, as well as medical device makers that specialize in knee replacements, insulin pumps and sleep apnea machines.

Kiplinger

Novo Nordisk CEO to face off with Bernie Sanders over 1,300% Ozempic markup in U.S.

Novo's Danish CEO Lars Fruergaard Jørgensen will face the U.S. Senate in September to defend Wegovy's and Ozempic's eye-watering prices.

Fortune

ASML, Novo Nordisk, Spotify Boast This Sign Of Stock Market Leadership

Spotify stock, ASML and Novo Nordisk, are in or near buy zones and boast this key signal of stock market leadership.

Investors Business Daily

In China, weight-loss drugs are becoming big business

Chinese pharmaceutical companies are racing to roll out weight-loss drugs amid the popularity of Ozempic.

Al Jazeera

S&P 500 Giants Lead Five Healthy Stocks Near Buy Points

Eli Lilly is in a buy zone, while weight-loss drug rival Novo Nordisk just forged a lower entry.

Investors Business Daily

Novo Helix T50 Carbon Fiber Tripod Kit review

This feature-packed travel tripod packs down unfeasibly small, yet extends reasonably tall

Digital Camera World

Get all your
news in one place.

100’s of premium titles.
One news app.

The Guardian - UK

Danish firm behind weight-loss drug Wegovy raises profit forecast to £15.3bn

Novo Nordisk, which is now Europe’s most valuable company, also reports strong sales of diabetes drug Ozempic

Investors Business Daily

Novo Nordisk Dips After Wegovy Sales Double, But Miss Analysts' Forecast

Novo Nordisk stock dipped Thursday after sales of weight-loss drug, Wegovy, nearly doubled, but missed even more bullish expectations.

Investors Business Daily

Weight Loss Leader Novo Nordisk Hits Buy Trigger In Stock Market Rebound

Novo Nordisk stock: The weight-loss drug leader hit a buy point in the recent stock market rebound and is one of the best stocks to watch.

Investors Business Daily

Why Wall Street Got Even More Excited About The Glucose Monitor — And How Dexcom, Abbott Labs Stand To Benefit

Metabolic health is all the rage, helped by the advent of weight-loss drugs and continuous glucose monitors. Can they change disease forever?

Get all your
news in one place.

100’s of premium titles.
One news app.

Investors Business Daily

IBD Stock Of The Day Novo Nordisk: Why A Pullback Is Bullish For The Weight-Loss Kingpin

The company leads the weight-loss drugs market with its blockbuster, Wegovy. But next-generation drugs are coming.

Investors Business Daily

Stock Market Rally Hits Fresh Highs As Nvidia, Novo Nordisk, Bitcoin Soar: Weekly Review

The Nasdaq and S&P 500 hit fresh all-time highs, with Nvidia and bitcoin continuing to surge.

Investors Business Daily

U.S. Stocks Aren't The Only Game In Town: Arm, Novo Please Investors

Arm Stock and Novo Nordisk stock topped this screen of leading global growth stocks. One of them is near a buy point.

Investors Business Daily

Why Dialysis Stocks DaVita, Fresenius Soared On Novo's Ozempic News

DaVita stock launched Tuesday after Novo Nordisk unveiled the results of its weight-loss drug in kidney disease patients.

Investors Business Daily

How The Red-Hot Obesity Space Could Help Eli Lilly Join The 1,000 Club

Lilly's new weight-loss drug could top $62 billion in 2030 sales, an analyst said Friday as he boosted his price target on Eli Lilly stock to 1,000.

Investors Business Daily

Weight-Loss Drugs Have One Big Problem. These Drugmakers Are Taking It On.

Weight-loss drugs from Novo Nordisk and Eli Lilly lead to massive weight loss. But not all of that weight loss is healthy.

Barchart

Europe's Most Valuable Stock Is a Must-Own Near 52-Week Highs

Despite concerns over its ability to meet surging semaglutide demand, this Danish pharmaceutical giant holds a dominant position in the diabetes and insulin markets - and now commands the lead in Europe's stock market, too. Here's why NVO is a must-own stock.

1 2 3 4 5

People

Lars Fruergaard Jørgensen

12 stories

Margaret Kaczor Andrew

11 stories

From analysis to the latest developments in health,
read the most diverse news in one place.

Organisations

Investor Business Daily

453 stories

ASML

434 stories

Read news from The Economist, FT, and more,
with one subscription

Topics

Places

Fourteen days free

Download the app

One app. One membership.
100+ trusted global sources.